IDH1/2 inhibitors are active in IDH1/2-mutated acute myeloid leukemia, but demonstrate limited efficacy in glioblastomas carrying IDH1/2 genetic alterations [98,99,100]. This evidence concerns the gene IDH1 and acute myeloid leukemia.